title: Effects of Y-24180, a receptor antagonist to platelet-activating factor, on allergic cutaneous eosinophilia in mice.
abstract: We examined the effects of Y-24180, a potent and long-acting antagonist to platelet-activating factor (PAF), on allergic cutaneous eosinophilia and cytokine production in the skin of mice. Mice sensitized actively with ovalbumin (OA) were challenged by an intradermal injection of OA solution. The number of inflammatory cells, including eosinophils and eosinophil peroxidase (EPO) activity reflecting eosinophil infiltration into the tissue increased in OA-challenged skin 12 hr after the challenge. The levels of interleukin-4 (IL-4) and IL-5 also increased significantly in the challenged skin 12 hr and 3-24 hr, respectively, but that of interferon-gamma (IFN-gamma) did not change. Then, we evaluated the effects of Y-24180, ketotifen, suplatast and prednisolone on the increase in EPO activity, IL-4 and IL-5. These drugs were orally administered once a day for 5 days beginning 4 days before the challenge. Y-24180 (10 mg/kg) and prednisolone (5 mg/kg) significantly suppressed these parameters. Suplatast did not affect EPO activity, but significantly decreased the levels of IL-4 and IL-5. Ketotifen had no effect on them. These results indicate that the inhibition of IL-4, IL-5 and PAF are required to suppress the cutaneous eosinophilia and Y-24180 contributes to the treatment of allergic cutaneous eosinophilia.
authors: Pharmaceutical Research, Yoshitomi Pharmaceutical Industries, Ltd., Fukuoka, Japan.
authors: S
authors: S
authors: Yamaguchi
authors: N
authors: N
authors: Tomomatsu
authors: M
authors: M
authors: Kagoshima
authors: T
authors: T
authors: Okumoto
authors: H
authors: H
authors: Komatsu
mesh_terms: D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis; D004802:Eosinophilia / Q000188:drug therapy*; D006967:Hypersensitivity / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D012871:Skin Diseases / Q000188:drug therapy*; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D001381:Azepines; D016207:Cytokines; D010972:Platelet Activating Factor; D014230:Triazoles; C068035:4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine